Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
124.7(c) 123.02(c) 125.66(c) 125.45(c) 129.86(c) Last
425 632 493 691 872 439 512 765 265 015 Volume
+0.72% -1.35% +2.15% -0.17% +3.52% Change
More quotes
Financials (USD)
Sales 2020 479 M - -
Net income 2020 -821 M - -
Net cash position 2020 1 206 M - -
P/E ratio 2020 -18,3x
Yield 2020 -
Sales 2021 804 M - -
Net income 2021 -680 M - -
Net cash position 2021 958 M - -
P/E ratio 2021 -22,9x
Yield 2021 -
Capitalization 15 087 M 15 087 M -
EV / Sales 2020 29,0x
EV / Sales 2021 17,6x
Nbr of Employees 1 323
Free-Float 99,2%
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic... 
More about the company
All news about ALNYLAM PHARMACEUTICALS, INC.
11/26ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 43rd Nasdaq Virtual Investo..
AQ
11/25ALNYLAM PHARMACEUTICALS : Announces Innovative Value-Based Agreement Framework f..
AQ
11/25ALNYLAM PHARMACEUTICALS : Announces U.S. Food and Drug Administration Approval o..
AQ
11/25ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 43rd Nasdaq Virtual Investo..
BU
11/24ALNYLAM PHARMACEUTICALS : Conference Call to Discuss FDA Approval of OXLUMO&trad..
PU
11/24ALNYLAM PHARMACEUTICALS : Announces Innovative Value-Based Agreement Framework f..
BU
11/24ALNYLAM PHARMACEUTICALS : Announces U.S. Food and Drug Administration (FDA) Appr..
BU
11/20ALNYLAM PHARMACEUTICALS : Receives Approval for OXLUMO in the European Union for..
AQ
11/19ALNYLAM PHARMACEUTICALS : Receives Approval for OXLUMO™ (lumasiran) in the..
BU
11/13ALNYLAM PHARMACEUTICALS : Reports Positive Interim Results from Ongoing Phase 1 ..
BU
11/06ALNYLAM PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results and Highl..
AQ
11/05ALNYLAM : 3Q Earnings Snapshot
AQ
11/05ALNYLAM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
11/05ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
AQ
11/05ALNYLAM PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results and Highl..
BU
More news
News in other languages on ALNYLAM PHARMACEUTICALS, INC.
11/20ALNYLAM PHARMACEUTICALS : erhält EU-Zulassung für OXLUMO™ (Lumasiran) zur ..
11/20ALNYLAM PHARMACEUTICALS : reçoit l'approbation de l'Union européenne pour OXLUMO..
10/18ALNYLAM PHARMACEUTICALS : reçoit un avis positif du CHMP pour OXLUMO™ (lum..
10/17ALNYLAM PHARMACEUTICALS : erhält positive CHMP-Stellungnahme für OXLUMO™ (..
10/16NOVARTIS : le CHMP recommande un nouvel anticholestérol
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 163,04 $
Last Close Price 129,86 $
Spread / Highest target 73,3%
Spread / Average Target 25,6%
Spread / Lowest Target -28,4%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Yvonne L. Greenstreet President & Chief Operating Officer
Michael W. Bonney Chairman
Jeffrey Poulton Chief Financial & Accounting Officer
Akshay K. Vaishnaw President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.12.76%15 087
IQVIA HOLDINGS INC.9.26%32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
PRA HEALTH SCIENCES, INC.-0.14%7 120
SYNEOS HEALTH, INC.12.08%6 932
NOVAVAX, INC.2,477.89%6 427